Think of this as a high-tech "seek and destroy" mission for prostate cancer. Usually, this targeted radiation is a late-game move, but experts are now testing it earlier, while the cancer still responds to hormone therapy. It’s basically sending in the elite squad before the situation gets truly desperate. 🎯✨
👇 Check it out:
The Lancet
The Lancet
[177Lu]Lu-PSMA-617 in metastatic androgen pathway modulator-sensitive prostate cancer
Lutetium-177 (177Lu)-PSMA-617 is a radioligand therapy that targets prostate-specific
membrane antigen (PSMA) and delivers β-particle radiation to PSMA-expressing cells
and the surrounding tumour microenvironment.1 177Lu-PSMA-617 was initially approved
in…
August 30, 2026 4
